Long-Term Safety and Efficacy of Olanzapine Long-Acting Injection in Patients With Schizophrenia or Schizoaffective Disorder

International Clinical Psychopharmacology - United States
doi 10.1097/yic.0000000000000038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Post-Injection Delirium/Sedation Syndrome in Patients With Schizophrenia Treated With Olanzapine Long-Acting Injection, I: Analysis of Cases

BMC Psychiatry
PsychiatryMental Health
2010English

Double-Blind, Randomized Trial Comparing Efficacy and Safety of Continuing Olanzapine Versus Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia or Schizoaffective Disorder

Therapeutics and Clinical Risk Management
2008English

The Effects of Psychoeducation on Long-Term Inpatients With Schizophrenia and Schizoaffective Disorder

Kurume Medical Journal
Medicine
2016English

A Critical Appraisal of Paliperidone Long-Acting Injection in the Treatment of Schizoaffective Disorder

Therapeutics and Clinical Risk Management
2016English

Treatment-Completion Rates With Olanzapine Long-Acting Injection Versus Risperidone Long-Acting Injection in a 12-Month, Open-Label Treatment of Schizophrenia: Indirect, Exploratory Comparisons

International Journal of General Medicine
Medicine
2012English

Prospective Trial of Customized Adherence Enhancement Plus Long-Acting Injectable Antipsychotic Medication in Homeless or Recently Homeless Individuals With Schizophrenia or Schizoaffective Disorder

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2013English

Long-Term Efficacy and Safety of Cardioneuroablation in Patients With Vagally Mediated Bradyarrhythmias

e-Journal of Cardiovascular Medicine
2020English

Romiplostim Monotherapy in Thrombocytopenic Patients With Myelodysplastic Syndromes: Long-Term Safety and Efficacy

British Journal of Haematology
Hematology
2017English

Long-Acting Phenothiazines in Schizophrenia

BMJ
1971English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy